Catalog No.: PC-49710Not For Human Use, Lab Use Only.
CDD-1653 (CDD1653) is a potent, selective inhibitor of BMP type 2 receptor BMPR2 with IC50 of 2.8 nM, >360-fold over ALK1, and is inactive versus all other type 1 and type 2 TGFβ family kinases.
CDD-1653 (CDD1653) is a potent, selective inhibitor of BMP type 2 receptor BMPR2 with IC50 of 2.8 nM, >360-fold over ALK1, and is inactive versus all other type 1 and type 2 TGFβ family kinases.
CDD-1653 inhibited BMP-mediated gene expression in mammalian cell cultures, suppressed BRE-reporter activity in a luciferase reporter (293T-BRE-Luc) assays with IC50 of 6.92 uM.
Pretreatment with CDD-1653 (25 uM) significantly decreased the phosphorylation of SMAD1/5 (pSMAD1/5) in BMP9 stimulation of pSMAD1/5 in HUVECs.
CDD-1653 is not only selective among the TGFβ family but also completely selective against >408 off-target kinases.
